Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

FLU-IGIV · NP-025

Plasma-derived product · Immune activation, directed at influenza A virus · developed by Emergent BioSolutions

Phase 2 Most advanced trial (none active)

EBS Developer

1 Registered trials

What is FLU-IGIV?

FLU-IGIV is an anti-influenza immunoglobulin intravenous formulation derived from human plasma. It is studied for treatment of influenza A infections, including H3N2 and H1N1 strains.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NP-025
Drug type: Plasma-derived product
Targets: influenza A virus
Mechanism: Immune activation, directed at influenza A virus
Therapy area: Infectious disease
Developer: Emergent BioSolutions (EBS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03315104	Phase 2	Influenza A H3N2	Completed	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza A H1N1Influenza A H3N2

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3

Sources

ClinicalTrials.gov NCT03315104

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind FLU-IGIV

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z